Library

RH-34

RH-34 is a compound which acts as a potent and selective partial agonist for the 5-HT2A serotonin receptor subtype. It was derived by structural modification of the selective 5-HT2A antagonist ketanserin, with the 4-(p-fluorobenzoyl)piperidine moiety replaced by the N-(2-methoxybenzyl) pharmacophore found in such potent 5-HT2A agonists as NBOMe-2C-B and NBOMe-2C-I. This alteration was found to retain 5-HT2A affinity and selectivity, but reversed activity from an antagonist to a moderate efficacy partial agonist.

Also known as: 3-[2-(2-methoxybenzylamino)ethyl]-1 H-quinazoline-2,4-dione, EZS-8-NBOMe

Classification

  • Chemical: Phenethylamine
  • Psychoactive: Psychedelic
  • Tag: Serotonergic

Effects

  • Dilated Pupils
  • Sedation
  • Physical Euphoria
  • Temperature Regulation Suppression
  • Difficulty Urinating
  • Nystagmus
  • Introspection
  • Emotionality Enhancement
  • Analysis Enhancement
  • Conceptual Thinking
  • Thought Connectivity
  • Anxiety Suppression
  • Visual Distortion
  • Color Enhancement
  • Perception Of Bodily Heaviness
  • Changes In Felt Bodily Form
  • Visual Acuity Enhancement
  • Pattern Recognition Enhancement

Routes of Administration

No route information available yet.

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu

RH-34 - Guía de sustancias de DrugsPRO

RH-34: RH-34 is a compound which acts as a potent and selective partial agonist for the 5-HT2A serotonin receptor subtype. It was derived by structural modification of the selective 5-HT2A antagonist ketanserin, with the 4-(p-fluorobenzoyl)piperidine moiety replaced by the N-(2-methoxybenzyl) pharma

Related pages